Experts find flaws in proposed Indian "Bayh-Dole" legislation
This article was originally published in Scrip
Executive Summary
An Indian bill, which encourages the commercialisation of intellectual property (IP) from government-financed R&D for the larger public good, is being widely debated, with some experts claiming that it is flawed and could stymie potential gains from the open source drug discovery model.
You may also be interested in...
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
Biocon Refutes Graft Charges After Regulatory Official Booked, Says Due Process Followed
Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.